Scientific Advisory Board

The scientific advisors and founders of Alnylam are among the world’s leaders in RNAi and in broad aspects of medical research.

Phillip Sharp, Ph.D.

Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences.


Dennis Ausiello, M.D.

Jackson Professor of Clinical Medicine at Harvard Medical School and Chief of Medicine at Massachusetts General Hospital.


David Bartel, Ph.D.

Member of the Whitehead Institute and Professor of Biology at MIT, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.


Katherine High, M.D.

Investigator at the Howard Hughes Medical Institute, the William H. Bennett Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and the Director of the Center for Cellular and Molecular Therapeutics at The Children’s Hospital of Philadelphia.


Robert Langer, Ph.D.

Germeshausen Professor at MIT and the only active member of all three U.S. National Academies – the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering.


Judy Lieberman, M.D., Ph.D.

Senior Investigator at the Immune Disease Institute, and Professor of Pediatrics, at Harvard Medical School, and the Director of the Division of AIDS at Harvard Medical School.


Daniel J. Rader, M.D.

Professor of Medicine and chief, Division of Translational Medicine and Human Genetics, at the Perelman School of Medicine at the University of Pennsylvania.


Paul Schimmel, Ph.D.

Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute, National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member, cofounder of Cubist, Alkermes and Repligen, and a founder and member of the Board of Directors of Alnylam.


Markus Stoffel, M.D., Ph.D.

Professor for Metabolic Diseases at the Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) in Zurich.


Thomas Tuschl, Ph.D.

Professor at Rockefeller University, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.


Phillip D. Zamore, Ph.D.

Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.